BIO:ON Insight #13 · Aug 25, 2026
Stand beside a giant, and you win. Stand against one, and you lose. Why?
Merck and Moderna's mRNA melanoma vaccine plus Keytruda extends recurrence-free survival, AstraZeneca halts a bispecific lung cancer trial, and Amylyx's GLP-1 antagonist cuts severe hypoglycaemia by 55%. Stand beside a giant and you win; stand against one and you lose. Why?
What I learned this week
If there's one line for this week, it's this: position beats possession. Honestly, what struck me most was that AstraZeneca, with the most sophisticated weapon, lost the hardest. Choosing where to put a drug turns out to be as hard as making a better one. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- Clinical Trials
Merck and Moderna's mRNA melanoma vaccine with Keytruda
Merck & Co.ModernaKeytruda
- Clinical Trials
AstraZeneca halts volrustomig's first-line lung cancer trial
AstraZenecavolrustomig
- Clinical Trials
Amylyx's avexitide succeeds in the Phase 3 LUCIDITY trial
Amylyxavexitide
AI summary
- 1Merck and Moderna's personalized mRNA cancer vaccine plus Keytruda significantly cut melanoma recurrence risk.
- 2AstraZeneca stopped a first-line lung cancer trial of its PD-1×CTLA-4 bispecific after it failed to beat Keytruda.
- 3Amylyx's GLP-1 antagonist avexitide succeeded in Phase 3 for post-bariatric hypoglycemia.
Relevant rolesClinical developmentR&DBD
Summary and tags generated by AI from the issue text.
References
- 1.
- 2.AstraZeneca halts volrustomig first-line lung cancer trial (opens in a new tab)
AstraZeneca media centre
- 3.Amylyx avexitide Phase 3 Lucidity results (opens in a new tab)
Amylyx investor news
Related insights
Other issues covering the same companies, drugs or topics